This data demonstrate that upregulation of the JNK-1/c-Jun pathway leads to the aberrant increasing of miR-21, and propose to miR-21 as a potential target to overcome cisplatin resistance of ovarian cancer cells. This evidence concerns the gene JUN and ovarian cancer.